An innovative Biotech company About Us
First-in-class disease-modifying products Discover our science
Therapies for neurodegenerative & traumatic disorders Our Pipeline

Our vocation is to develop first-in-class innovative drugs to treat patients with degenerative or traumatic neurological disorders
with high unmet medical needs.

Our ambition is to improve the recovery of the functionality and the quality of life of patients.

Our Discovery

During embryogenesis, a small organ named Subcommisural Organ (SCO) located in the dorsal roof of the brain differentiates and secrets the SCO-spondin, a large multi-domain protein widely distributed in the CNS and with potent activity during neurogenesis.

Learn more

Our Products

Our products are first-in-class multi-target patented peptides with high potential in many CNS disorders, as demonstrated via distinctive and multifunctional mechanism of action on neural cells.

Learn more

Diseases focus

Neurological disorders are diseases of the central and peripheral nervous system. These disorders are of major clinical problems with high unmet medical needs and currently no satisfactory treatment.

Learn more

News

Neuroscience Virtual Partnering – 2020

Axoltis Pharma will attend Neuroscience Virtual Partnering on November 9-12. Yann Godfrin, Chief Executive Officer and Luca Bolliger, Chief Business Officer, will be delighted to meet you there and discuss potential partnerships for the development of our innovative drug-candidate for neurological disorders !

BIO Europe Digital 2020

Axoltis Pharma announces to attend BIO Europe 2020 Digital on October 26-29, with participation to the One-on-One Partnering event. This … Read more

WFNR & SOFMER 2020

Axoltis Pharma announces to attend the 11th World Congress for NeuroRehabilitation (WFNR annual meeting) jointly with the 35th Congress of the … Read more

BIO 2020

Axoltis Pharma announces to attend BIO International Convention 2020 Digital on June 8-12, with participation to the Bio One-on-One Partnering … Read more